These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 12517251)
41. Changes in body mass index in children with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors. Shafferman A; Fontaine KR; Cron RQ; Beukelman T J Rheumatol; 2014 Jan; 41(1):113-8. PubMed ID: 24293573 [TBL] [Abstract][Full Text] [Related]
42. Advances in the medical treatment of juvenile rheumatoid arthritis. Onel KB Curr Opin Pediatr; 2000 Feb; 12(1):72-5. PubMed ID: 10676778 [TBL] [Abstract][Full Text] [Related]
43. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314 [TBL] [Abstract][Full Text] [Related]
44. [Effectiveness and safety of biological therapy with adalimumab]. Fehér J; Lengyel G Orv Hetil; 2009 Jun; 150(26):1215-22. PubMed ID: 19546078 [TBL] [Abstract][Full Text] [Related]
46. Potential Effect of Tumor Necrosis Factor Inhibitors on Trabeculectomy With Mitomycin C for Patients With Juvenile Idiopathic Arthritis-Related Uveitic Glaucoma: A Retrospective Analysis. Leinonen S; Kotaniemi K; Kivelä T; Majander A JAMA Ophthalmol; 2015 Nov; 133(11):1323-8. PubMed ID: 26402863 [TBL] [Abstract][Full Text] [Related]
47. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Guzman J; Oen K; Tucker LB; Huber AM; Shiff N; Boire G; Scuccimarri R; Berard R; Tse SM; Morishita K; Stringer E; Johnson N; Levy DM; Duffy KW; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey S; Bruns A; Campillo S; Benseler S; Chédeville G; Schneider R; Yeung R; Duffy CM; Ann Rheum Dis; 2015 Oct; 74(10):1854-60. PubMed ID: 24842571 [TBL] [Abstract][Full Text] [Related]
48. Non-steroidal anti-inflammatory drugs and slow-acting anti-rheumatic drugs in juvenile rheumatoid arthritis. Fujikawa S Acta Paediatr Jpn; 1993 Oct; 35(5):447-53. PubMed ID: 8256630 [TBL] [Abstract][Full Text] [Related]
49. Development of germinoma during the treatment of systemic-onset juvenile idiopathic arthritis with infliximab. Takezaki S; Okura Y; Ichikawa M; Suzuki D; Ohshima J; Kaneda M; Cho Y; Yamada M; Kawamura N; Iguchi A; Kobayashi I; Ariga T Mod Rheumatol; 2012 Aug; 22(4):621-4. PubMed ID: 22072226 [TBL] [Abstract][Full Text] [Related]
50. Insurance Delays in Initiation of Tumor Necrosis Factor Inhibitors in Children With Juvenile Idiopathic Arthritis. Roberts JE; Fan M; Son MBF JAMA Netw Open; 2022 Apr; 5(4):e228330. PubMed ID: 35446398 [TBL] [Abstract][Full Text] [Related]
51. Systemic juvenile idiopathic arthritis: New insights into pathogenesis and cytokine directed therapies. Pardeo M; Bracaglia C; De Benedetti F Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):505-516. PubMed ID: 29773270 [TBL] [Abstract][Full Text] [Related]
52. Systemic Juvenile Idiopathic Arthritis: Diagnosis and Management. Kumar S Indian J Pediatr; 2016 Apr; 83(4):322-7. PubMed ID: 26916892 [TBL] [Abstract][Full Text] [Related]
53. Clinical and biochemical characteristics of children with juvenile idiopathic arthritis. Ahmed S; Ali SR; Ishaque S; Sami N J Coll Physicians Surg Pak; 2014 Jul; 24(7):498-502. PubMed ID: 25052974 [TBL] [Abstract][Full Text] [Related]
54. Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France? The CORPUS cohort study. Saraux A; Benichou J; Guillevin L; Idbrik L; Job-Deslandre C; Sibilia J; Soudant M; Wendling D; Guillemin F Clin Exp Rheumatol; 2015; 33(5):602-10. PubMed ID: 26315585 [TBL] [Abstract][Full Text] [Related]
55. Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis. Kahn R; Berthold E; Gullstrand B; Schmidt T; Kahn F; Geborek P; Saxne T; Bengtsson AA; Månsson B Acta Paediatr; 2016 Apr; 105(4):427-32. PubMed ID: 26707699 [TBL] [Abstract][Full Text] [Related]
56. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register. Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940 [TBL] [Abstract][Full Text] [Related]
57. Rapid Resolution of Erosive Psoriatic Juvenile Idiopathic Arthritis With Anti-Tumor Necrosis Factor Therapy. Felix MD; Ostrov BE J Clin Rheumatol; 2021 Dec; 27(8S):S688-S689. PubMed ID: 33136694 [No Abstract] [Full Text] [Related]
58. Juvenile idiopathic arthritis: classification, clinical presentation and current treatments. Dannecker GE; Quartier P Horm Res; 2009 Nov; 72 Suppl 1():4-12. PubMed ID: 19940489 [TBL] [Abstract][Full Text] [Related]
59. Multicenter inception cohort of enthesitis-related arthritis: variation in disease characteristics and treatment approaches. Gmuca S; Xiao R; Brandon TG; Pagnini I; Wright TB; Beukelman T; Morgan EM; Weiss PF Arthritis Res Ther; 2017 May; 19(1):84. PubMed ID: 28464909 [TBL] [Abstract][Full Text] [Related]
60. Management of Juvenile Idiopathic Arthritis 2015: A Position Statement from the Pediatric Committee of the Canadian Rheumatology Association. Cellucci T; Guzman J; Petty RE; Batthish M; Benseler SM; Ellsworth JE; Houghton KM; LeBLANC CM; Huber AM; Luca N; Schmeling H; Shiff NJ; Soon GS; Tse SM; J Rheumatol; 2016 Oct; 43(10):1773-1776. PubMed ID: 27698103 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]